TrialScope Launches Free EudraCT Results Conversion Service
JERSEY CITY, N.J., April 7, 2015 /PRNewswire/ -- TrialScope, the global leader in clinical trial transparency and compliance solutions, today announced the availability of Convert, a free online clinical trial data conversion service. The complimentary service enables users to quickly and efficiently reuse clinical trial results data that was previously reported to the U.S. registry (clinicaltrials.gov) and convert it to the appropriate format for submission to the European registry (EudraCT).
Clinical trial sponsors face a looming deadline for reporting results in Europe. For eligible clinical trials that ended between July 21, 2013 and July 21, 2014, sponsors are required to post results by July 21, 2015. The data entry burden for only one study is significant and many sponsors have numerous study results to report. Sponsors can gain access to the free conversion service from the TrialScope website at convert.trialscope.com.
TrialScope's Chief Strategy Officer, Thomas Wicks, commented, "TrialScope's complimentary EudraCT conversion service will provide sponsors with an opportunity to maintain compliance while simplifying the effort to do so. The service immediately reduces the data entry burden by as much as 85% for clinical trial results disclosures."
Early feedback from users who previewed the service was very positive with one top pharma team rating the service 10 out of 10 for ease of use and speed. Another team estimated that they would save 5-8 hours per study on data entry alone using TrialScope's Convert service.
Mike Forgash, CEO, TrialScope, added, "Our free EudraCT conversion service will help clinical trial sponsors realize time and resource savings not only by alleviating redundant data entry, but also by leveraging the quality assurance and review processes for data that has already been approved for disclosure in the U.S. The conversion will also ensure alignment of the data across registries, which is a significant compliance challenge for most global sponsors."
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
